Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.

Hepatology

Division of Gastroenterology and Hepatology, and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN.

Published: June 2014

Unlabelled: Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis. Here we tested the hypothesis that cholangiocyte senescence is a pathophysiologically important phenotype in PSC. We assessed markers of cellular senescence and senescence-associated secretory phenotype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals by fluorescent in situ hybridization (FISH) and immunofluorescence microscopy (IFM). We tested whether endogenous and exogenous biliary constituents affect senescence and SASP in cultured human cholangiocytes. We determined in coculture whether senescent cholangiocytes induce senescence in bystander cholangiocytes. Finally, we explored signaling mechanisms involved in cholangiocyte senescence and SASP. In vivo, PSC cholangiocytes expressed significantly more senescence-associated p16(INK4a) and γH2A.x compared to the other three conditions; expression of profibroinflammatory SASP components (i.e., IL-6, IL-8, CCL2, PAI-1) was also highest in PSC cholangiocytes. In vitro, several biologically relevant endogenous (e.g., cholestane 3,5,6 oxysterol) and exogenous (e.g., lipopolysaccharide) molecules normally present in bile induced cholangiocyte senescence and SASP. Furthermore, experimentally induced senescent human cholangiocytes caused senescence in bystander cholangiocytes. N-Ras, a known inducer of senescence, was increased in PSC cholangiocytes and in experimentally induced senescent cultured cholangiocytes; inhibition of Ras abrogated experimentally induced senescence and SASP.

Conclusion: Cholangiocyte senescence induced by biliary constituents by way of N-Ras activation is an important pathogenic mechanism in PSC. Pharmacologic inhibition of N-Ras with a resultant reduction in cholangiocyte senescence and SASP is a new therapeutic approach for PSC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167827PMC
http://dx.doi.org/10.1002/hep.26993DOI Listing

Publication Analysis

Top Keywords

cholangiocyte senescence
24
senescence sasp
16
psc cholangiocytes
12
experimentally induced
12
senescence
11
cholangiocytes
9
n-ras activation
8
primary sclerosing
8
sclerosing cholangitis
8
psc
8

Similar Publications

Catching the STING: Unlocking senescence and PD-L1 in PBC.

Clin Res Hepatol Gastroenterol

January 2025

Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine (CRSA), Paris, France; Foundation for Innovation in Cardiometabolism and Nutrition (IHU-ICAN), Paris, France. Electronic address:

View Article and Find Full Text PDF

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Cells

September 2024

SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy.

Article Synopsis
  • Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that, if left untreated, can lead to severe liver damage, including cirrhosis, and may require a transplant.
  • The disease is influenced by genetic factors and specific environmental triggers, with an imbalance in gut microbiota (dysbiosis) being a significant factor.
  • Current treatments include bile acid-based therapies like ursodeoxycholic acid, but new therapies such as elafibranor and seladelpar are being explored to enhance treatment options and personalize care for patients.
View Article and Find Full Text PDF

Background & Aims: Senescence has been reported to have differential functions in cholangiocytes and hepatic stellate cells (HSCs) during human and murine cholestatic disease, being detrimental in biliary cells and anti-fibrotic in HSCs. Cholestatic liver disease is associated with loss of intestinal barrier function and changes in the microbiome, the mechanistic cause of which is undetermined.

Methods: Intestinal samples were analysed from controls and patients with primary sclerosing cholangitis, as well as wild-type (WT) and p16-3MR transgenic mice.

View Article and Find Full Text PDF

Central role for cholangiocyte pathobiology in cholestatic liver diseases.

Hepatology

September 2024

Department of Medicine, Division of Gastroenterology and Hepatology, Mayo College of Medicine and Science, Mayo Clinic, Rochester, Minnesota, USA.

Cholangiopathies comprise a spectrum of chronic intrahepatic and extrahepatic biliary tract disorders culminating in progressive cholestatic liver injury, fibrosis, and often cirrhosis and its sequela. Treatment for these diseases is limited, and collectively, they are one of the therapeutic "black boxes" in clinical hepatology. The etiopathogenesis of the cholangiopathies likely includes disease-specific mediators but also common cellular and molecular events driving disease progression (eg, cholestatic fibrogenesis, inflammation, and duct damage).

View Article and Find Full Text PDF

Interaction of high lipogenic states with titanium on osteogenesis.

Bone

November 2024

Department of Gastroenterology and Hepatology, Erasmus MC, Erasmus University Medical Center, Rotterdam, the Netherlands.

As obesity rates continue to rise, the prevalence of metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), a new term for Nonalcoholic Fatty Liver Disease (NAFLD), also increases. In an aging population, it is crucial to understand the interplay between metabolic disorders, such as MetALD, and bone health. This understanding becomes particularly significant in the context of implant osseointegration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!